{"name":"On Target Laboratories, LLC","slug":"on-target-laboratories-llc","ticker":"","exchange":"","domain":"ontargetlaboratoriesllc.com","description":"On Target Laboratories, LLC is a biotechnology company focused on the development of targeted imaging agents and therapeutics for cancer. The company's lead product, CYTALUX (pafolacianine) injection, is currently marketed, while OTL38 for Injection is in Phase 3 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"OTL38 for Injection","genericName":"OTL38 for Injection","slug":"otl38-for-injection","indication":"Ovarian cancer (folate receptor alpha positive)","status":"phase_3"}]}],"pipeline":[{"name":"OTL38 for Injection","genericName":"OTL38 for Injection","slug":"otl38-for-injection","phase":"phase_3","mechanism":"OTL38 is a folate receptor alpha-targeted immunoconjugate that delivers a cytotoxic payload to cancer cells expressing folate receptor alpha.","indications":["Ovarian cancer (folate receptor alpha positive)","Non-small cell lung cancer (folate receptor alpha positive)","Triple-negative breast cancer (folate receptor alpha positive)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPY3lZYS11TkYxQ1RUbE9OaXJzT1NaYXR0OWtBdTFlbW94Ujd1QjRNamlfTWNzeld6cWY5U3lid1kzaTJIOUNYNlotcl9TZzdRcVhjRFNvSTRrYTN2OVkxdU5rVVZ1ajdUV0drdkQ4SkJ6Mi0wbVRleWQ0NzJsejc1LVdReTNjM0xVbWxyZXhsY25tRlV3S0hOZ1lyazFrREhNSXBPWTNWWmxHRkwwa1lHckt6TFJhb3NCWkh0NGNPSWNSVkRrUUhfUFRnZUNLeTlMd2VHZWg2Ul9uaUZ6SG5R?oc=5","date":"2026-02-24","type":"trial","source":"Reuters","summary":"Novo Nordisk, United Laboratories 'triple G' drug trial shows 19.7% weight loss - Reuters","headline":"Novo Nordisk, United Laboratories 'triple G' drug trial shows 19.7% weight loss","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOSWNZUF9YTllnbE1HeDdVbTNhTXd1di0yanp0OXZfS2ZBSUlBc3FPRVZlb050MWJ4V3RrVW9mc09YTVhxNU51VWVMRGVSbFpBWlZNbjJUem9hTFJpQnRXVjBkbUNETmdiZjJrRzhLQjBPY182TlJBZnQwSFdTQk8xalhfUk1XUGh6TGpfTkFKcko?oc=5","date":"2026-01-14","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Lilly and NVIDIA unveil $1B co-innovation lab in SF - drugdiscoverytrends.com","headline":"Lilly and NVIDIA unveil $1B co-innovation lab in SF","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPVnVjRDFDZHBRZ2x3ay1TUlNDM1NKSDdqa2JWdUhDMV9uN0d0TGdfMm1MWVVOakJXZHE1M0hSNUFIaXg2cUlPbkpxQ1VtMnZrX1FEMDNWTERXZWtrUGlYaW5hODE1Qmk2OE9JLXNSeHRtTEJveDRoRzZ5ZF9sRjJxZkd0ZHo3YnZOQTN5LQ?oc=5","date":"2025-09-30","type":"pipeline","source":"Contract Pharma","summary":"Nelson Laboratories Launches RapidCert - Contract Pharma","headline":"Nelson Laboratories Launches RapidCert","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQY21SZWdfZGZtSFZHVkJJdFdJNXBZYmpCQ1MwUnFfTlRxeUQ2aXhJckZwRnpQQ0NBRkVGcDE1SmpKZmc5V0pOblphdmR5QnlaYktCLUxUZTY1c3ZNLUNVby1JSGQ3X3FFQW9JUDd5UHQ5c0lJeU1CUWY5U3U4RG9mV09FeVMwMjZFdnZsVXF1WkVYbjhEVVhUSGFHNzA2MDVYRTYyZmdR0gGrAUFVX3lxTE9ZSnh2cHV2a1ZXRnUzZzhPRjE5V29KaGZOekNPRnRJMmRQWWM3azRlRzlkUEtIaHc0R2tRUlhmRmJzb2hHR0pra2prd0loVVhoNVV1bmlxWkw2MDJ0S1RQNHpLdUpSLUZ6Z3JJb0JOY0lUMWs2LUFmYWRoTUNjSkpHYVNob2puUURQS1FQN19rTnVpRllHc2ZDWUI0M25xSWJxOVNaYm5RNmJ0NA?oc=5","date":"2025-03-25","type":"pipeline","source":"CNBC","summary":"Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly - CNBC","headline":"Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQc3RlNWhfRThjUXh2RHdsNWdoOGwzV2JMc1BrSVJBa3pnU3dhVjNUU2QtcmJIQzZvRDJrNnViSkE1ZWZieFd3YmUtYWRMV2VoVDN3RUlFTFJOeG5sdnl6SUd1TUVrQm9QLU0xMGNpX1FZZU84TF9NVHVabU9QODg2VXpSNFdGY3ZJZjk5X1V0Y2NLVXJGaGhFdGx1ekk2R3pyZnBSRTBvNTRxMEpnV1JuZzM1UElNOGV1X000LU04cVRfaGE2ZVE5M0xmRGowNFE?oc=5","date":"2025-01-27","type":"pipeline","source":"24-7 Press Release Newswire","summary":"Marquis Who's Who Honors Sumith A. Kularatne, PhD, for Expertise in Drug Development - 24-7 Press Release Newswire","headline":"Marquis Who's Who Honors Sumith A. Kularatne, PhD, for Expertise in Drug Development - 24-7 Press Release Newswire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPYko4eVZoekpjc01tcWthdUFFTnVQNHFKMXQ1c2VNY2lZT3MyaU1JbUJOUUdlOFdfaURoSXRLb3R0cE1sdC1QR011ZURMakw1RjZOVHlYNFV5NDMtWHVhRFJjNGJnRkpHRmFyMi1mMVo0cmJUZ3dXaWhDQlBGM18ta0dsNHNXX2pqTTdPZlFMeHdmNE1nbkdQMTBraEpGaFE?oc=5","date":"2024-03-25","type":"pipeline","source":"Fierce Pharma","summary":"BioDesign: Accelerating the Momentum of Bioconjugate Therapeutics - Fierce Pharma","headline":"BioDesign: Accelerating the Momentum of Bioconjugate Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxON21qcVVwb1FJMTJ2SURWcS1rSlc4eUJUb211UDlza2psbDRJUGVjalZwdTFBb29hREF2Rml1cHdmWU9mVExPZTBGVkdKTXBRWXk4VnhsdUpQV0VCOE5OYVhoMi1vZEwza3J3WmQtYlZRLVBvUlNRZWljOUhvUXVGTW55ZTIwLU9DcWIyUnQ0dUFTR2k4dVFyOHpxTWdKaXFaWFh1VkgyS3ZkNWN1M0hhMzJBam9IbTZvSC1yLTZ1ZklIYks2cUItRy1EWHA3X3hFNGcxYVJ3?oc=5","date":"2024-01-03","type":"pipeline","source":"PR Newswire","summary":"On Target Laboratories Names Scott Huennekens as Executive Chairperson of the Board - PR Newswire","headline":"On Target Laboratories Names Scott Huennekens as Executive Chairperson of the Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOX20tNlpCZ05KdHpvZEJaOWNZWE9kMFhFaUhLSnlzd1VncWpwQ1NSbWRwYnlZSzQ3R0FOdHkwZUxKZk8yOElaQ2M3WGtRV0o5TFRoQTh6TWxZaFhnRjdVdU1rbDMzV2JLNFZ2VUhYVkpmZ3ZWMXdGNXZEMFdyb0ZIUFk2aGVqeE13eldMdWxUTUp6OTVNZlBJamxXekpya2hucEc0c19DVFR1SE1iNGpYYi1EZkkzUm9IR0lOaUl4QXg4NjMtcVAwRFBtZWI5eEo3VGZBVWlLcDdZUHNuVlNYYTVPc0tEMS1fWHc?oc=5","date":"2023-11-16","type":"pipeline","source":"PR Newswire","summary":"On Target Laboratories Secures $30 Million for Commercialization of CYTALUX® (pafolacianine) injection - PR Newswire","headline":"On Target Laboratories Secures $30 Million for Commercialization of CYTALUX® (pafolacianine) injection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxOVkdPTW1jTFlMMXZYcy12czUxbThZb0VSZk84UGcwNF9BYnp3dlRNR0RjNmdmbEd2UER5dWRsWkRoMnBpYkkyaURaT3AybnY2Y2QxVXQwcjlLM3p1QlUtLWQ5OWhySE9mblJKMDFheTIxMEJJZGVoRWx5VG1CR0tFQXRCcTJSdDBJNHpuWTF4TzR5aDFSNWh5bmNGZExQS3dDc3YyNnlFUGhQLVNKbTdqYk4yN3JWc2cwTEE2cFk1X3VZV011SF9MWl9XYXlGR1E2TERmaWN2WXZDczh2N1l0NUZVWGd5eEhhakhvVUJrN3g5UHV4cm9mQmU1RHJYY3cwalZEbk1UMmJ5YXQ0ZE1yUHlBZEdISzkxUkdXSFdQODkzUQ?oc=5","date":"2023-08-10","type":"pipeline","source":"PR Newswire","summary":"On Target Laboratories Granted New Technology Add-On Payment (NTAP) for CYTALUX® (pafolacianine) injection in Ovarian and Lung Cancer Indications - PR Newswire","headline":"On Target Laboratories Granted New Technology Add-On Payment (NTAP) for CYTALUX® (pafolacianine) injection in Ovarian an","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOd3BzaVNYSks2VWV4clgyTWFDVW51d2xiSW5ucDBLUzBpMjZ4M1NUMHlwMUpmM1BDV25QMm1QZC0zZGVCUTUzemlPV0JXVDFzOFpJeFZCT1BIbi1yREMyWDRxZEpfT2YxYm5LTTdWbzI2cXNzZ3FZRlNfTndvcGhiY3NvWThDV2xOaTZnNGdBRHhwR0hzaEZjV19SVUxQQ09RNnNCbjVZRUhhaER6MU9ZUlN5OUM?oc=5","date":"2021-05-12","type":"pipeline","source":"Private Equity Stakeholder Project PESP","summary":"After Millions in Settlements, H.I.G. Capital Faces Multiple Health Care Fraud Suits - Private Equity Stakeholder Project PESP","headline":"After Millions in Settlements, H.I.G. Capital Faces Multiple Health Care Fraud Suits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPUF96amdOMGN2S0tNU3dJUUdJQk5OWV91NjNjQkRpQlFiY0NFR1RYVk9yWUs4NUI0Rlo4d2V6OEJWd2szYnJWbjl3TmMycVpwSFVOaGZvUl9hVEREZzNfNzZ3R01oNFEtVV9jT01RSmhHUm5maUVEOERmeUhoeGlBUUJWM3pYOE54YkNubENMQjVmZ2M?oc=5","date":"2020-02-10","type":"pipeline","source":"Fierce Biotech","summary":"Illuminating cancer surgery with a dye that makes tumors glow - Fierce Biotech","headline":"Illuminating cancer surgery with a dye that makes tumors glow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxPMWJyV2d4ZjZpbmRUREU4MEpzaXhCM01FazRCWVJNZlVqbDRydE0xanhINW04VHVWQ2NNX2poSG9PMkVDRzBVdlBSVnY5bFRCS0Y4MXdaZC1IOUZCNmozQnlHeDhFRkhNZHlHYkdpYUd1Z3JSR21TT2xHZVJMaXF2VTRCLUxmUG9Lc3JxSFE4SDlKMER2em1NQWxvWjFKcmthclF2SDUyRUg2ZUcyQkNWdnBueU9ZOTM4czJGdGFJVUdvTmtoNHpha0U0TTZ6b2NGd3h3UmVwV2pGZ2xsdVUxcXdUUzQ0dkdSSmVJRWFOcWFXWC1PRU5mUjlJMjY1alRwcW01Y0h3?oc=5","date":"2018-11-08","type":"pipeline","source":"Purdue University","summary":"Successful Purdue entrepreneurs provide targeted advice to faculty and staff entrepreneurs entering startup world - Purdue University","headline":"Successful Purdue entrepreneurs provide targeted advice to faculty and staff entrepreneurs entering startup world","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}